Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale
Boehringer Ingelheim and AimedBio have entered a global collaboration and license agreement to develop a new antibody-drug conjugate (ADC) targeting a tumor-selective marker present in various hard-to-treat cancers12.
The deal is valued at up to $991 million, covering an upfront payment, development, regulatory, and commercial milestones, with AimedBio also eligible for royalties on sales37.
The new ADC asset, expected to enter first-in-human studies in 2026, is described as potentially best-in-class and represents part of Boehringer's expanding oncology and ADC pipeline123.
The agreement is part of Boehringer's strategic efforts, driven by its subsidiary NBE Therapeutics, to grow its precision oncology portfolio12.
EyePoint Pharmaceuticals has announced a $150 million stock sale to raise funds, although additional specific details on this transaction are limited in the provided search results8.
Sources:
1. https://www.globenewswire.com/news-release/2025/10/15/3167043/0/en/Boehringer-Ingelheim-advances-cancer-antibody-drug-conjugate-portfolio-with-asset-from-AimedBio.html
2. https://via.ritzau.dk/pressemeddelelse/14626799/boehringer-ingelheim-limited?publisherId=90446&lang=en
3. https://www.biospace.com/business/boehringer-ingelheim-bets-up-to-nearly-1b-in-adc-play-with-aimedbio-deal
7. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-partnership-helps-advance-our-cancer-adcs-portfolio
8. https://www.benzinga.com/general/biotech/20/02/15244252/the-daily-biotech-pulse-eyepoint-in-licenses-eye-disorder-drug-biomarin-cfo-quits-rockwell-medica